BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SAPA-GP - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://sapagp.org
X-WR-CALDESC:Events for SAPA-GP
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240111T200000
DTEND;TZID=America/New_York:20240111T210000
DTSTAMP:20260423T164908
CREATED:20231227T195252Z
LAST-MODIFIED:20231227T195252Z
UID:4689-1705003200-1705006800@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Jan 2024
DESCRIPTION:REGISTER HERETong ZhangPh.D.\, CBO/CFO & Co-Founder\, VelaVigoTong Zhang\, PhD. Dr. Tong Zhang is the co-founder\, CBO/CFO of VelaVigo. Prior to VelaVigo he was Chief Business Officer at Shanghai Genechem\, Managing Director at C-Bridge Capital (CBC)\, a healthcare focused PE\, responsible for sourcing\, evaluation and execution of investment opportunities focusing on China market\, as well as incubating and managing portfolio companies.\nPrior to CBC Tong was head of Corporate BD at WuXi AppTec\, responsible for strategic partnership and M&A\, head of Business Development for MSD China and pan-regional BD lead for at Merck & Co.\, head of Business Development at EKR Therapeutics\, a VC-backed specialty pharmaceutical company in the US. Tong also had investment experience as a Director at ESP Equity Partners\, and equity analyst covering the US pharmaceutical industry for Credit Suisse in New York. Tong worked as a consultant for ISO HealthCare Consulting (now part of the Monitor Group) and Defined Health\, leading strategy consulting firms in the biopharmaceutical industry.\nTong received his Ph.D. in Biology from Columbia University and a B.S. degree in Biology from Wuhan University in China. He also performed post-doctoral research at Sloan-Kettering Cancer Center in New York in the lab of Nobel Laureate Dr. James Rothman.Jing YangPh.D.\, CSO & Co-Founder\, BaseCure TherapeuticsJing Yang\, Ph.D.\, Chief Scientific Officer\, BaseCure Therapeutics， Jing currently serves as the Chief Scientific Officer\, Co-founder and Board Director of BaseCure Therapeutics，a siRNA therapeutic startup company with proprietary platform technology and a rapidly growing pipeline. Jing is an accomplished drug hunter with over 20 years of experience leading multidisciplinary discovery research teams. In her previous roles at Johnson & Johnson and Bristol-Myers Squibb\, Jing led the progression of numerous innovative drugs through the pipeline and successfully delivered three IND candidates for clinical research. Her expertise spans from small molecules\, biologics\, stem cells to RNAi research. Jing also held a number of leadership roles in Corporate and Non-Profit Organizations\, most notably the Global Lead of Pan Asian Network at Bristol-Myers Squibb in 2019-2021 and President of Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) in 2019-2020.\nJing received her BS degree in Physical Chemistry at Sichuan University in China and her Ph.D degree in Glycobiology at Albert Einstein College of Medicine in New York. After completing her postdoctoral trainings at New England Medical Center and University of Pennsylvania\, Jing held an Instructor position at the Center for Experimental Therapeutics and Department of Pharmacology at University of Pennsylvania. Jing is an author of 40 peer reviewed manuscripts and inventor of 14 patent applications.Lee QianCFA\, Investment Manager\, Baillie GiffordLee QIAN. Lee Qian is an investment manager at Baillie Gifford’s Positive Change Strategy. He joined Baillie Gifford in 2012 and is a CFA Charterholder. Lee graduated BA (Hons) in Economics and Management from the University of Oxford in 2012. Lee has a keen interest in sustainable development\, across a range of topics including health\, climate\, and education. All views expressed will be his own.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-jan-2024/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/12/2024-Jan-11-webinar-featured.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240111T120000
DTEND;TZID=America/New_York:20240111T130000
DTSTAMP:20260423T164908
CREATED:20231218T234511Z
LAST-MODIFIED:20231218T234511Z
UID:4684-1704974400-1704978000@sapagp.org
SUMMARY:Job Seekers Roundtable Virtual Meeting
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/job-seekers-roundtable-virtual-meeting/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/12/job-seeker-feature.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240109T200000
DTEND;TZID=America/New_York:20240109T210000
DTSTAMP:20260423T164908
CREATED:20231218T234013Z
LAST-MODIFIED:20231218T234013Z
UID:4675-1704830400-1704834000@sapagp.org
SUMMARY:How to Write Effective Email Virtual Workshop
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/how-to-write-effective-email-virtual-workshop/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/12/effective-email-feature.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231213T083000
DTEND;TZID=America/New_York:20231213T093000
DTSTAMP:20260423T164908
CREATED:20231119T234957Z
LAST-MODIFIED:20231120T003151Z
UID:4661-1702456200-1702459800@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Dec 2023
DESCRIPTION:Register HereLes FuntleyderCFO\, Investor\, Professor\, AuthorMr. Funtleyder has a 20-year track record of healthcare investing and is currently a Healthcare Portfolio Manager at E Squared Capital Management where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. While at E squared Les has had five IPO exits including serving as CFO of one of the portfolio companies.\nPrior to E Squared\, Mr. Funtleyder was the Director of Strategic Investments and Communications for Opko Health. In this role he participated in over $2 billion in transactions including acquisitions\, strategic investments\, and licensing deals. He also led all corporate and product communication efforts for the $5 billion company.\nLes was a long-time portfolio manager and healthcare strategist for the Miller Tabak Health Care Transformation Fund (Symbol: MTHFX) a mutual fund dedicated to investing in transformative healthcare companies.\nHe joined Miller Tabak\, after managing a healthcare portfolio for Provident Advisors\, a hedge fund in Minneapolis\, Minnesota. Before joining Provident\, Les worked as a medical device analyst at UBS Warburg. He also covered Biotechnology stocks at Bigelow and Company. His industry experience includes directing clinical and business research at Innovative Health Solution\, a joint venture of Merck and Wyeth\, and as a consultant to HMOs and hospitals for Coopers & Lybrand and Health Strategies Group. He started his healthcare career at Empire Blue Cross/Blue Shield where he developed his approach to determining how products and services should get reimbursed\, a skill that is vital in making healthcare companies successful.\nMr. Funtleyder wrote Healthcare Investing: Profiting from the New World of Pharma\, Biotech\, and Health Care Services (McGraw Hill)\, which bridges the gap between health reform\, innovation and investing. He is widely quoted in the Wall Street Journal\, the New York Times\, and the Financial Times\, and is a frequent guest on CNBC\, Bloomberg and NPR for his perspective on the healthcare sector and its constituent companies. He is also a consulting partner to Bluecloud Health\, a Sub-Saharan healthcare private equity fund and an advisor to Zentalya\, a venture capital firm focused on South American healthcare. He currently sits on the Board of Directors for Applied Therapeutics (NASDAQ: APLT) and Reviva Pharma (NASDAQ: RVPH).\nLastly\, Les is currently an Adjunct Professor of Public Health at Columbia University. Les earned his Master of Public Health from Columbia University Mailman School of Public Health\, and studied English and Economics at Tulane University.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-dec-2023/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/11/1213-webinar-featured-1.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231108T080000
DTEND;TZID=America/New_York:20231108T170000
DTSTAMP:20260423T164909
CREATED:20231031T152125Z
LAST-MODIFIED:20231031T152125Z
UID:4646-1699430400-1699462800@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Nov 2023
DESCRIPTION:REGISTER NOWNikhil Mutyal\, Ph.D.Executive Director\, Business Development and Licensing\, Pacific Hub\, Merck and Co.Nikhil Mutyal\, Ph.D. is Executive Director\, Business Development and Licensing in Pacific Hub for Merck and Co (known as MSD outside of United States) based in San Francisco. Dr. Mutyal leads BD&L efforts for Oncology\, Neuroscience and Cardiometabolic diseases for therapeutic opportunities from companies and research initutes based in Western US/CAN\, SE Asia\, ANZ. Dr. Mutyal’s professional career spans across management consulting for pharma/biotech and BD roles across various companies. Dr. Mutyal received his Ph.D. in Biomedical Engineering (Cancer Research) from Northwestern University and has B.S.+M.S. in Medicinal Chemistry from Indian Institute of Technology\, Kanpur.Yang Qiu\, Ph.D.Chief Scientific Officer and US GM\, Duality BiologicsDr. Yang Qiu has over 20 years of MNC drug discovery and development experience with demonstrated success of leading drug discovery\, translational medicine and early clinical development programs. She contributed to the discovery and progression into clinic of over 15 drug candidates and drug approvals including the most recent FDA BTD Patritumab Deruxtecan (HER3-DXd) \nPreviously as Co-chair of cross-ADC program\, Senior Director of Translational Medicine at Daiichi Sankyo; Director\, Head of Translational and Biomarker Research at Janssen; Director\, Head of Molecular Discovery Research at GSK China\nPostdoc in Human Genomics at Lawrence Berkeley National Lab\, PhD in Molecular Biology from University of Texas at Austin\, and college from University of Science and Technology in ChinaLiang Xiao\, Ph.D.COO and Co-founder\, MediLink TherapeuticsDr. Liang Xiao is the COO and Co-founder of MediLink Therapeutics. Dr. Liang Xiao is primarily responsible for ADC drug preclinical development and external cooperation in business development at MediLink. With 16 years of experience in both academia and the biopharmaceutical industry\, Dr. Xiao previously served as the VP of Biologics R&D at Kelun-Biotech\, where he was responsible for the development of multiple innovative biologics from 2013 to 2020. These projects resulted in global licensing agreements with multinational companies\, totaling over $12 billion in value. \nDr. Xiao has successfully led 15 monoclonal antibody\, bispecific antibody\, and ADC projects into clinical stages. Among them\, two monoclonal antibody projects and one ADC project have been submitted for BLA. Additionally\, one ADC project is currently in Phase III clinical stage\, and four ADC projects are in Phase I clinical stage. \nDr. Xiao holds a Bachelor’s degree in Life Sciences from the University of Science and Technology of China\, as well as a Ph.D. degree in Chemical Engineering from the University of Southern California.Shunfei Yan\, Ph.D.Medical Evaluation Manager\, AstraZeneca ChinaShunfei is currently a medical evaluation manager at AZ China where he is responsible for searching & evaluating potential external partnership opportunities. Before joining AZ\, Shunfei spent multiple years in venture capital domain where he served as an investment manager at Fosun Health Capital and Lingang Wonder-of-Land Capital with a focus on innovative medicines. Shunfei received his PhD degree in oncology from the University of Melbourne where he conducted his study in synthetic lethality. Before that\, he obtained his Master and Bachelor degree in Biological Sciences from Fudan University.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-nov-2023/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/10/Nov-webinar-featured.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231010T100000
DTEND;TZID=America/New_York:20231010T110000
DTSTAMP:20260423T164909
CREATED:20231003T160044Z
LAST-MODIFIED:20231031T150006Z
UID:4636-1696932000-1696935600@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Oct 2023
DESCRIPTION:Register NowChris Sheldon Ph.D.Dr. Chris Sheldon is among the best biopharma dealmakers\, and his impressive track record includes AstraZeneca/Daiichi’s ~$13bn partnership of DS8201 and Dato-Dxd\, AstraZeneca’s $6.4b acquisition of Acerta over its Acalabrutinib\, which is included in the sensation book “In Blood and Money”\, during his time at AstraZeneca as the head of Oncology BD. Shortly after he took the helm of the GSK’s BD\, he led the $2B acquisition of Bellus Health and also closed the deal with WuXi Biologics over their multiple bi- & multi-specific T cell engagers for oncology.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-oct-2023/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/10/featured.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231008T110000
DTEND;TZID=America/New_York:20231008T150000
DTSTAMP:20260423T164909
CREATED:20230919T000606Z
LAST-MODIFIED:20230919T000606Z
UID:4625-1696762800-1696777200@sapagp.org
SUMMARY:SAPA-GP 2023 Fall Picnic
DESCRIPTION:register now
URL:https://sapagp.org/event/sapa-gp-2023-fall-picnic/
LOCATION:Upper Providence Blackrock Park\, 1286 Black Rock Road\, Phoenixville\, PA\, 19460\, United States
CATEGORIES:Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2023/09/https___cdn.evbuc_.com_images_594364999_202745421483_1_original.jpeg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230920T210000
DTEND;TZID=America/New_York:20230920T220000
DTSTAMP:20260423T164909
CREATED:20230907T144313Z
LAST-MODIFIED:20231003T154735Z
UID:4617-1695243600-1695247200@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Sept 2023
DESCRIPTION:This event has ended. Please scroll down for the recording.Catherine PearceDHSc\, MBADr. Pearce started her career in 1997 at Hoffman-LaRoche\, then at Merck launching therapeutics in the cardiovascular space. In 2001\, Dr. Pearce joined a small CRO\, Medpace\, as a Clinical Project Manager. She led hundreds of global Phase 1-4 studies in a variety of therapeutic areas\, including neurology\, diabetes\, lipid-lowering\, kidney diseases\, and obesity. She started the first business development team and marketing teams at Medpace in 2011. In 2013\, Dr. Pearce joined Teva as VP\, R&D\, leading a new division dedicated to evaluating generics for repurposing. One of the most recognizable efforts to come from this program was the approval of Uzedy in 2023 for the treatment of schizophrenia. Uzedy was approved in partnership with Medincell\, which was a collaboration her team had spearheaded. In 2015\, Dr. Pearce decided to come back to her hometown of Cincinnati\, OH to co-found a biotech incubator\, CinRx. The idea of launching a biotech portfolio company seemed timely Dr. Pearce: the thesis was to take early-stage or “shelved” assets from pharma\, biotech\, or academia and develop them through proof-of-concept to be acquired by large pharma with commercial capabilities. During her time at CinRx\, Dr. Pearce developed 6 “Cin” portfolio companies in areas such as oncology\, obesity\, gastroparesis\, and hypertension. When CinCor’s Board decided the strategic exit of this company’s novel aldosterone synthase inhibitor was a public offering\, Dr. Pearce spun out with the organization to build the company’s infrastructure and help take it public. After the asset\, baxdrostat\, demonstrated its value in the Phase 2 BrigHtn study published in the New England Journal of Medicine\, the company was eventually acquired by AstraZeneca in February 2023 in a transaction worth up to $1.8B.\nToday\, Dr. Pearce is once again embarking on the idea that forming a company around early-stage or shelved assets is a necessary endeavor. This time\, though\, she is using her experience to build stronger clinical development teams\, Advisory Boards\, strategic partners\, and financial backers to evaluate novel therapeutics and design the ideal trials to demonstrate the benefits and safety of life-saving medicines for the patients that need them. As the CEO of newly formed JucaBio\, she is excited about the future of drug development and the possibilities of bringing additional therapeutics to patients worldwide in areas of high unmet medical needs.\nIn addition to sitting on a number of private biotech Boards\, Dr. Pearce is an advisor to several start-ups and a Board of Trustee Member at Xavier University\, where she received her undergraduate education and MBA. She received her Doctorate in Health Sciences from Nova Southeastern University. Dr. Pearce is married with 3 children and is a fitness enthusiast\, book lover\, traveler\, and avid cook. Dr. Pearce lives by three creeds: say “yes” many more times than you say “no\,” never ask someone to do work you are unwilling or unable to do yourself\, and — importantly — always look for a little fun along the way.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/09/featured-image-9-20-2023-webinar.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230727T200000
DTEND;TZID=America/New_York:20230727T213000
DTSTAMP:20260423T164909
CREATED:20230714T154859Z
LAST-MODIFIED:20230714T154859Z
UID:4564-1690488000-1690493400@sapagp.org
SUMMARY:Beyond FDA Approval: Assessing Pharmaceutical Market Access Risk for Drug Development Strategy
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/beyond-fda-approval-assessing-pharmaceutical-market-access-risk-for-drug-development-strategy/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/07/0727-webinar-feature.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230623
DTEND;VALUE=DATE:20230625
DTSTAMP:20260423T164909
CREATED:20230607T230200Z
LAST-MODIFIED:20230607T230200Z
UID:4537-1687478400-1687651199@sapagp.org
SUMMARY:2nd Annual SAPA-GP @Philly Cell Gene Therapy Conference
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/2nd-annual-sapa-gp-philly-cell-gene-therapy-conference/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AtPhilly,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2023/06/cgt_featuered.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230609T210000
DTEND;TZID=America/New_York:20230609T223000
DTSTAMP:20260423T164909
CREATED:20230607T004735Z
LAST-MODIFIED:20230607T004735Z
UID:4531-1686344400-1686349800@sapagp.org
SUMMARY:ASCO2023 Recap: The Winners\, Losers\, and Black Horses
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/asco2023-recap-the-winners-losers-and-black-horses/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/06/ASCO_featured_recap.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230530T210000
DTEND;TZID=America/New_York:20230530T223000
DTSTAMP:20260423T164909
CREATED:20230526T142648Z
LAST-MODIFIED:20230526T142648Z
UID:4495-1685480400-1685485800@sapagp.org
SUMMARY:Preview of ASCO by BioSpark/ISWTC/SAPA-GP
DESCRIPTION:REGISTER HERESpeakersModeratorOrganizers
URL:https://sapagp.org/event/preview-of-asco-by-biospark-iswtc-sapa-gp/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/05/featuered-image.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230517T180000
DTEND;TZID=America/New_York:20230517T203000
DTSTAMP:20260423T164909
CREATED:20230514T002908Z
LAST-MODIFIED:20230514T005959Z
UID:4465-1684346400-1684355400@sapagp.org
SUMMARY:@Philly Company Showcase & Networking Dinner
DESCRIPTION:
URL:https://sapagp.org/event/philly-company-showcase-networking-dinner/
LOCATION:Jin Ding Restaurant\, 1051 Conestoga Rd\, Bryn Mawr\, PA\, 19010\, United States
CATEGORIES:AtPhilly,Career Events,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2023/05/pdf_20230510_095448_0000.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230331T120000
DTEND;TZID=America/New_York:20230401T190000
DTSTAMP:20260423T164909
CREATED:20230118T023035Z
LAST-MODIFIED:20230329T122928Z
UID:4163-1680264000-1680375600@sapagp.org
SUMMARY:SAPA-GP 2023 Annual Conference
DESCRIPTION:SAPA-GP 2023 Annual Conference: Embracing New Technologies in a Changing World \nRegister NowAgendaMarch 31st – April 1st\, 2023 (In-Person)\nSheraton Valley Forge Hotel\n480 N Gulph Rd\, King of Prussia\, PA 19406\nClick here to register or scan the QR code on the right.\nDuring the past few years\, the pharmaceutical industry has experienced dramatic changes due to COVID 19 pandemic and technological advancements.  Many of those changes are transforming the industry and speeding up the pace of new drug development. On the technological front\, new drug targets have been discovered at ever increasing speed. AI assisted drug discovery is opening new frontiers. Digital technologies\, decentralized clinical studies\, and real-world evidence are reshaping clinical development. On the business front\, creative business models are weathering the current market downturn and rejuvenating fresh investment\, mergers and acquisitions (M&A)\, and partnership around the world. Regarding patient access\, in responding to skyrocketing price tags of new drugs\, adaptive payment mechanisms have been devised in hope of delivering lifesaving medicines to patients in a sustainable way. \nOn Mar 31st – Apr. 1st\, 2023\, SAPA-GP will hold 2023 annual conference at King of Prussia\, PA. There will be 5 Parallel Tracks: \n\nScientific: Pioneering a New Era of Drug Discovery & Development: Novel Targets\, Innovative Platforms\, and Recent Regulations\nClinical: New Trends in Clinical Development\nBusiness: The Business Engine of New Drug Development: Fundraising\, BD\, and Commercialization\nMarket Research: Promoting Patient Access after Regulatory Approval\nCareer: Career Development\, Diversity\, Labor Law\, and Roundtable Discussion\n\nWe are excited to have Dr. Amir Kalali and Dr. Virginia Man-Yee Lee\, two well-known experts as our keynote speakers\, to share insights from both scientific and clinical perspectives. Moreover\, Dr. Tim Opler will discuss M&A transactions across the pharmaceutical industry\, and Dr. Joga Gobburu will talk about model-informed drug development. \nCheck out our list of top-notch speakers and sponsors: \nRegister NowStay tuned for more speakers and agenda. \nBecoming our Annual Conference sponsors with these benefits:\n• Exhibition booths at the Annual Conference\n• Company showcases in the conference brochure and website\n• Guest speaker slots in parallel sessions\n• A platform for reaching out to potential business partners\n• Far-reaching market penetration via email blasts\, LinkedIn\, and WeChat groups\n• Great opportunities for talent recruitment… and more! For sponsorship opportunities\, please contact: bd@sapa-gp.org \nDo you want to become a Volunteer for SAPA-GP Annual Conference and future events? please contact: sapagp@sapa-gp.org \nRefer to our website for the Refund and Transfer policy and Student Discount. \nSAPA-GP\, supported by the collective wisdom of professionals in the pharmaceutical industry\, strives to shine insight into how the pharmaceutical industry is adapting to the evolving environment and transforming itself into the new era of biopharma 2.0. The SAPA-GP 2023 Annual Conference will be a unique opportunity for people to come together to celebrate the transformation underway\, and more importantly\, to brainstorm how to ride the tide to success. \nCheck out more events on SAPA-GP website or scan the QR code below.
URL:https://sapagp.org/event/sapa-gp-2023-annual-conference/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AC,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2023/01/banner.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230126T200000
DTEND;TZID=America/New_York:20230126T213000
DTSTAMP:20260423T164909
CREATED:20230119T131125Z
LAST-MODIFIED:20230120T033331Z
UID:4225-1674763200-1674768600@sapagp.org
SUMMARY:Humanized mouse models to accelerate drug development - SAPA-GP Webinar Jan 26\, 2023
DESCRIPTION:Register HereSanti s. ChenAssociate Director\, Immunology and Oncology\, GemPharmatechSanti is a research scientist and business development professional with over 10 years of experience in autoimmune disease\, immunology\, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology\, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia\, focusing on pediatric leukemia and therapies. Her projects include testing agents’ efficacy and mechanisms such as navitoclax\, venetoclax\, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards.Sponsored by GemPharmatechGemPharmatech\, a leading provider of mouse models and preclinical services\, offers a one-stop solution for in vivo studies with a collection of more than 20\,000 strains including KO/cKO\, humanized\, disease\, germ-free and custom models\, as well as custom breeding services. \nSponsored by GemPharmatech; Contact: sales@gempharmatech.us
URL:https://sapagp.org/event/4225/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/01/Featured-pic.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221209T090000
DTEND;TZID=America/New_York:20221209T153000
DTSTAMP:20260423T164909
CREATED:20221201T171457Z
LAST-MODIFIED:20221201T173243Z
UID:4104-1670576400-1670599800@sapagp.org
SUMMARY:SAPA-GP Career Development Workshop
DESCRIPTION:Ignite Your Career GrowthWhat are your career goals for 2023? \n\nGet promoted?\nChange to a different role?\nBe more effective in your current role?\nMove from a technical to business role?\n\nIf so\, this Career Development Workshop is for YOU! \nCome learn and build your network \nREGISTER HERE!FEATURED SPEAKERSDavid CraginSenior Director\, Product ScienceTeva PharmaceuticalsCheryl PaesVP\, Head of MarketingCenter for Breakthrough MedicinesJing YangCo-founder & Board DirectorBaseCure TherapeuticsJamie HuangFounderPrinceton Leadership AcademyJoe LingleChief People OfficerCenter for Breakthrough MedicinesPan PanDirector of Business DevelopmentAkeso\, Inc.Audrey GreenbergCo-Founder & Chief Business OfficerCenter for Breakthrough MedicinesAgenda8:30am – 9:00am \n9:00am – 9:30am \nRegistration \nOpening remark & Keys to On-line and In-person networking \nDavid Cragin \nSenior Director\, Product Science \nTeva Pharmaceuticals \n9:30am – 10:00am \nTopic 1: The secrets of HR \nJoe Lingle \nChief People Officer \nCenter for Breakthrough Medicines \n10:00am – 10:30am \n1030am – 11:00am \nNetworking Break I \nTopic 2: Take a Chance on Unexpected Opportunities \nJing Yang \nCo-founder & Board Director \nBaseCure Therapeutics \n11:00am – 11:30am \nPanel Discussion \nAudrey Greenberg \nCo-Founder and Chief Business Officer \nCenter for Breakthrough Medicines \nJing Yang \nCo-founder & Board Director \nBaseCure Therapeutics \n11:30am – 1:00pm \n1:00pm – 1:40pm \nLunch Break \nTopic 3: Getting off the Sticky Floor \nJamie Huang \nFounder \nPrinceton Leadership Academy \n1:40pm – 2:00pm \n2:00pm – 2:40pm \nNetworking Break II \nTopic 4: A Path from R&D to Business Development \nPan Pan \nDirector of Business Dvelopment \nAkeso\, Inc \n2:40pm – 3:10pm \nPanel Discussion \nCheryl Paes \nVP\, Head of Marketing \nCenter for Breakthrough Medicines \nPan Pan \nDirector of Business Development \nAkeso\, Inc. \nScan QR code for registration\, or follow this registration link: \nhttps://www.eventbrite.com/e/sapa-gp-2022-career-development-workshop-igniting-your-career-growth-tickets-467770322627
URL:https://sapagp.org/event/sapa-gp-career-development-workshop/
LOCATION:The Center for Breakthrough Medicines\, 411 Swedeland Road\, #100\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:Career Events,Event,In Person,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2022/12/featured.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221110T200000
DTEND;TZID=America/New_York:20221110T213000
DTSTAMP:20260423T164909
CREATED:20221104T222406Z
LAST-MODIFIED:20221105T122416Z
UID:4080-1668110400-1668115800@sapagp.org
SUMMARY:Mouse Models for Disease Mechanism Studies and Drug R&D
DESCRIPTION:Register HereXiang Gao\, Ph.D.Founder and Chairman of GemPharmatechXiang Gao is an alumina of Nanjing University. He received his Ph.D. degree from Thomas Jefferson University in 1994\, then did his postdoctoral training at the Jackson Lab. In 2000\, Xiang was recruited back as professor at Nanjing University. Where he founded both Model Animal Research Center of NJU and National Resource Center of Mutant Mice of China. He was the associate dean of Medical School and director for the State Key Laboratory of Pharmaceutical Biotechnology. Xiang is the recipient for Cheung Kong Scholar from Ministry of Education and Distinguished Young Scholar from National Science Foundation. His lab has been focused on understanding the physiological homeostasis of metabolic and immunological processes. He has been funded by multiple national grants and published more than 200 research papers. Xiang is recipient of many national and international awards\, including the National Science and Technology Progress Award. In 2017\, Xiang founded GemPharmatech (GPT) which has become the leading company for animal model generation and application. GPT is the largest mutant mouse resource center in the world and now holds more than 22\,000 mutant mouse strains. GPT went IPO early this year at STAR market in Shanghai Exchange.Sponsored by: GemPharmatech\nGemPharmatech\, a leading provider of mouse models and preclinical services. With a collection of 20\,000+ strains\, GPT offers KO/cKO\, humanized\, disease\, and custom models\, as well as a one-stop solution for in vivo studies. Contact: brook.white@gempharmatech.us
URL:https://sapagp.org/event/mouse-models-for-disease-mechanism-studies-and-drug-rd/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2022/11/Nov.-10-Webinar-feature.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220915T200000
DTEND;TZID=America/New_York:20220915T213000
DTSTAMP:20260423T164909
CREATED:20220910T144808Z
LAST-MODIFIED:20220911T223208Z
UID:3944-1663272000-1663277400@sapagp.org
SUMMARY:Accelerating Cell & Gene Therapy Innovations: NK Cell Therapy\, Preclinical Solutions\, and CRO
DESCRIPTION:Register HereDongfang LiuAssociate Professor/Director of Immunoassay Development ProgramDongfang Liu\, Ph.D.\, an Associate Professor and Director of Immunoassay Development Program at the Department of Pathology\, Immunology and Laboratory Medicine in Rutgers University- New Jersey Medical School. In 2012\, Dr. Liu was recruited to Baylor College of Medicine as a tenure-track Assistant Professor in the Department of Pediatrics\, and Pathology & Immunology\, before joining Houston Methodist Research Institute (HMRI) as an Assistant Professor in 2015. In 2018\, Dr. Liu was promoted to an Associate Professor in HMRI. Dr. Liu did his Ph.D. and postdoctoral training on natural killer (NK) cells. After completing the postdoctoral training\, he joined Ragon Institute of MGH\, MIT and Harvard in 2011 as a senior research scientist\, where he worked on HIV-specific immune cell dysfunction. Dr. Liu’s research is primarily focused on the immunobiology of NK and chimeric antigen receptor (CAR)-NK cells. He has more than 20 years’ experience in NK cell research. Dr. Liu has published research papers in top-tier journals\, including Nature Immunology\, Immunity\, Nature Communications\, JACI\, Proc. Natl. Acad. Sci.\, and others. Dr. Liu serves on several editorial boards for multiple journals and as a reviewer for a number of journals and several grant agencies.Santi ChenAssociate Director\, Immunology and Oncology\, GemPharmatechSanti is a research scientist and business development professional with over 10 years of experience in autoimmune disease\, immunology\, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology\, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia\, focusing on pediatric leukemia and therapies. Her projects include testing agents’ efficacy and mechanisms such as navitoclax\, venetoclax\, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards. \nSponsored by GemPharmatechGemPharmatech\, a leading provider of mouse models and preclinical services. With a collection of 21\,000 strains\, GPT offers KO/cKO\, humanized\, disease\, and custom models\, as well as a one-stop solution for in vivo studies. \nContact: keila.woods@gempharmatech.us
URL:https://sapagp.org/event/accelerating-cell-gene-therapy-innovations-nk-cell-therapy-preclinical-solutions-and-cro/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2022/09/Flyer-Sept-15_feature.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220617
DTEND;VALUE=DATE:20220619
DTSTAMP:20260423T164909
CREATED:20220428T020820Z
LAST-MODIFIED:20220911T023723Z
UID:3688-1655424000-1655596799@sapagp.org
SUMMARY:@Philly Cell & Gene Therapy Annual Conference 2022
DESCRIPTION:
URL:https://sapagp.org/event/philly-cell-gene-therapy-annual-conference-2022/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AtPhilly,Event,In Person
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2022/04/Screen-Shot-2022-04-16-at-08.29.05.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220524T200000
DTEND;TZID=America/New_York:20220524T213000
DTSTAMP:20260423T164909
CREATED:20220511T191641Z
LAST-MODIFIED:20220911T022309Z
UID:3816-1653422400-1653427800@sapagp.org
SUMMARY:Finding your Pathway to Success - Career meeting
DESCRIPTION:Register Here
URL:https://sapagp.org/event/finding-your-pathway-to-success-career-meeting/
LOCATION:PA
CATEGORIES:Career Events,Event,Webex Meeting
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220415T120000
DTEND;TZID=America/New_York:20220416T190000
DTSTAMP:20260423T164909
CREATED:20220314T012254Z
LAST-MODIFIED:20220911T023850Z
UID:3622-1650024000-1650135600@sapagp.org
SUMMARY:Turbo Charging Innovation in the New Decade of Life Sciences --- US-China Biopharma Congress - SAPA-GP 2022 Annual Conference (Hybrid)
DESCRIPTION:Turbo Charging Innovation in the New Decade of Life Sciences  Sheraton Valley Forge Hotel\n480 N Gulph Rd\, King of Prussia\, PA 19406\nor\nthrough Online Platform and Mobile App \nRegister Here中国地区平台注册AgendaProgram Brochure As the flagship event of SAPA-GP\, our Annual Conference attracted over 1\,000 attendees each year\, featuring presentations and panel discussions by distinguished speakers and panelists from academia\, industry\, and regulatory authorities\, to provide opportunities for scientific exchange\, public health education\, networking\, career development\, and business collaborations. After two years of postponement due to the pandemic situation\, we have decided that it is time to host the annual conference again\, through a hybrid platform\, which allows for both local participants to enjoy the social networking again\, and global participants to connect from all over the world without geographic restrictions. You can join us from Anywhere!\n\n1 week final count down! Register now or onsite. \n3 Parallel Tracks:\n\nScientific track: Redefining pharmaceutical innovation from bench to bedside\nBusiness track: Unleashing the power from scientific breakthroughs and entrepreneurship (Co-branding with BioKatalyst)\nCareer track: Preparing life scientists for the future\n\n\nAgenda and Speakers Highlights below:\n\nFor detailed Agenda\, please check here or click on the Agenda Tab.\n\nEnjoy the benefits of Hybrid Platform: \nOnline: \n\n\nAccess to mobile app for program navigation and live stream of all presentations.\nSchedule 1-1 meetings with all attendees including sponsors through mobile app and online platform.\nRandom matchmaking and speed networking\n1 month access to cloud recording of presentation videos\n\nOnsite:\n\nAll benefits from online\nFood & beverage included (worth $80/person)\nFriday: Snack Bar (4-5pm)\, free coffee\nSaturday: Lunch box (11:30 am-12:30pm) & Snack Bar (4-5pm)\, free coffee\nAttend company show cases and opportunities of direct contact/mock interview with hiring manager from 10+ prestigious pharmaceutical companies.\nSocial networking with speakers and other attendees from pharmaceutical industry\nAttend career development workshops and join 1-1 SAPA-GP mentoring program\n\nSponsors
URL:https://sapagp.org/event/turbo-charging-innovation-in-the-new-decade-of-life-sciences-us-china-biopharma-congress-sapa-gp-2022-annual-conference-hybrid/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AC,Event
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2022/03/AC2022.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210715T200000
DTEND;TZID=America/New_York:20210715T213000
DTSTAMP:20260423T164909
CREATED:20210702T001923Z
LAST-MODIFIED:20221201T192628Z
UID:3502-1626379200-1626384600@sapagp.org
SUMMARY:Cell & Gene Therapy (CGT) Rapid Growth in China: What Could be Your Share of the Pie?
DESCRIPTION:Register HereSpeakers:Amit AgarwalManaging Director\, Life Sciences San Francisco\, CA Amit is a Managing Director in Deloitte Consulting’s Life Sciences practice. Amit has more than 25 years of management consulting experience and has led multiple projects in both strategy and operations Amit co-leads the Next Generation Therapies practice. The practice focuses on advising clients on taking advantage of and/or developing strategic responses to new disruptive technologies in cell and gene therapies space. Amit has worked with Life Science clients in the U.S. Europe and Asia on high-impact projects.\nAmit also has experience as Vice President at Leerink Swann & Co.\, a boutique investment bank focused on the life sciences. He helped innovative life science companies raise capital\, identify merger and acquisition targets and negotiate strategic partnerships and alliances. He helped his clients generate nearly $1 billion of market value through the deals he helped broker.\nAmit publishes extensively in the business press and in peer reviewed academic journals on personalized medicine. Amit has presented at multiple conferences in North America\, South America and Europe and worked with industry associations on value-based care and risk sharing contracts in light of new technology paradigms.\nAmit holds an MBA in finance and technological innovation from the MIT Sloan School of Management and a bachelor’s degree in history and premed from Occidental College. Prior to business school\, Amit conducted research in neurobiology at the California Institute ofTechnology and was an American diplomat posted in China and the Middle East. Annie XuSpecialist Leader\, Life Sciences and Health Care\, Deloitte Consulting\, USAI am a core member of Deloitte’s NextGen Practice\, with a focus on helping cell and gene companies set up their supply chain and commercial platform to launch their products globally. I co-lead Deloitte’s Industry Working Group (IWG)\, working closely with industry leaders to design patient-centric solutions that provide CGT access to a broader patient population.\nRelevant experiences:\n1. Developed a digital strategy to support the first gene-editing product launch in the US and EMEA\n2. Performed the market landscape assessment for cell and gene therapies and developed the investment strategy for a PE firm\n3. Led patient journey development and market sizing for an ultra-rare disease gene therapy\, and develop launch strategy in Saudi\, Russia\, Japan\, and Brazil\nSupported commercial site certification across 80+ hospitals within the US for a CAR-T product\n4. Drove the global launch readiness for the most expensive gene therapy product outside of the US\, with a projected $1B sales revenue in 2020David Xie\, PhDPartner\, NextGen expertI’m a Partner based in Shanghai\, China with a focus on biotech and next generation therapies practice. We often take a China specific view and help clients to understand the intricate and fast-evolving policies environment and what it means for entry strategy\, regulatory path\, market access\, and go-to-market models. We also tackle next-generation specific issues such as site certification and supply chain visibility. My experience in CGT:\n1. Led multiple projects with leading overseas biopharma companies to help define China product regulatory paths\, market access and GTMs including CAR-T\, targeted oncology drugs\, and rare disease drugs\n2. Worked on global supply chain and China commercial excellence to define China entry and supply chain models for Cell & Gene Therapies\n3. Worked on the launch of multiple CAR-T products access and pricing strategy in China\n4. Worked on the companion genetic diagnosis tests clinical development and GTM assessment as part of the CGT product portfolio\n5. Represent the Deloitte Next Generation Therapies practice in China with thought leadership on driving In China For China business modelsJohn Law Strategy and Business Design Manager\, Deloitte Consulting\, ChinaJohn is a Shanghai based Manager at the Strategy & Business Design service\nline\, also known as Monitor Deloitte and now part of Strategy\, Analytics and M&A offering portfolio\, of Deloitte Consulting. He studied Biomedical Sciences at University of Oxford where he specialized in scientific data analysis as well as experimental testing; through which he developed a research oriented and data driven approach to solving problems.\nJohn possesses a diverse skill set from strategy to operations in Life Sciences\nand Health Care consulting. His strong written and verbal communication skills also contributed to his successful track record in interacting with clients across levels. John is fluent in English\, Mandarin Chinese and Cantonese Chinese.\nSelected project experience:\n• Assessed China competitive landscape as well as pricing and reimbursement environment for a leading British multinational pharmaco’s hepatocellular carcinoma CAR T; designed likely market access journey for client’s CAR T by formulating various reimbursement scenarios and price volume relationship\n• Evaluated China go to market model options for a leading Japanese multinational pharmco’s portfolio of gene therapies having identified relevant regulatory barriers; designed entry roadmap from entity set up\, clinical trials\, product and materials import to commercialization\n• Estimated China market size and attractiveness for a leading Japanese multinational medical device company’s cell processing center; identified use cases and customer segments and developed unique value propositions\nJohn holds a Master and a Bachelor degree in Biomedical Sciences from University of Oxford.
URL:https://sapagp.org/event/cell-gene-therapy-cgt-rapid-growth-in-china-what-could-be-your-share-of-the-pie/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2021/07/July-15-Webinar-e1625185124573.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
END:VCALENDAR